弥漫型大B细胞淋巴瘤EZH2、XIAP和Survivin蛋白表达水平及意义

目的探讨弥漫型大B细胞淋巴瘤Zeste同源物增强子2(EZH2)、X连锁凋亡抑制蛋白(XIAP)和生存素(Survivin)蛋白表达水平及意义。方法选取弥漫型大B细胞淋巴瘤组织92例作为观察组,同时选取反应性增生淋巴结组织50例作为对照组,采用免疫组化染色法检测EZH2、XIAP和Survivin蛋白表达。结果观察组EZH2、XIAP和Survivin蛋白阳性表达率分别为77.17%、55.43%和60.87%,明显高于对照组(P<0.05)。观察组临床分期Ⅲ~Ⅳ期EZH2、XIAP和Survivin蛋白表达阳性率分别为90.70%、86.05%和81.40%,明显高于临床分期Ⅰ~Ⅱ期(P<0.05);EZH2与XIAP、Survivin蛋白表达呈正相关(γ=0.547、0.360,P均<0.05),XIAP与Survivin蛋白表达呈正相关(γ=0.581,P<0.05)。结论弥漫型大B细胞淋巴瘤EZH2、XIAP和Survivin蛋白表达水平上调,与临床分期有一定关系,三者间存在相关关系。     

不同时期COPD患者血清DcR3、Survivin表达水平及临床意义

目的 探讨不同时期慢性阻塞性肺疾病(COPD)患者血清诱饵受体3(DcR3)、凋亡抑制蛋白(Survivin)表达水平及临床意义。方法 选取2018年9月—2019年12月本院收治的92名COPD患者为研究对象,其中稳定型COPD 50例,急性加重期COPD 42例;同期本院健康体检者88例为对照组。测定各组研究对象血清DcR3、Survivin水平及肺功能指标。 与对照组[DcR3(106.54±48.35)pg/mL,Survivin(98.85±26.59)pg/mL]比较,稳定期组和急性加重期组血清DcR3[(395.23±123.85)pg/mL,(1 248.81±213.59)pg/mL]、Survivin [(267.54±84.69)pg/mL,(1 233.95±307.26)pg/mL]水平升高;与稳定期组比较,急性加重期组血清DcR3、Survivin水平升高。与对照组比较,稳定期组和急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001);与稳定期组比较,急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001)。随着低氧血症严重程度的增加,COPD患者血清DcR3、Survivin水平逐渐增加(P<0.001)。多因素logistics回归分析显示,高水平DcR3、Survivin、IL-12、hs-CRP为COPD病情的危险因素(P<0.001)。DcR3、Survivin与FEV、FEV1 /FVC呈负相关,与IL-12、TNF-α、hs-CRP呈正相关(P<0.001)。 COPD稳定期、急性加重期患者血清DcR3、Survivin表达水平升高,且DcR3、Survivin与COPD病情严重程度呈正相关。     

Survivin-shRNA对视网膜母细胞瘤HXO-RB44细胞自噬及凋亡的影响

目的:研究Survivin-shRNA对视网膜母细胞瘤HXO-RB44细胞自噬及凋亡的影响。方法:培养视网膜母细胞瘤HXO-RB44细胞，构建Survivin-shRNA载体。按照处理不同分为Survivin-shRNA组、GFP组和CON组。分别采用流式细胞术检测Survivin-shRNA对HXO-RB44细胞凋亡和细胞周期的影响，应用MTT法检测Survivin-shRNA对HXO-RB44细胞活性的影响，Western blot法检测Survivin-shRNA对HXO-RB44 细胞自噬相关蛋白LC3、p62 与mTOR 表达的影响。结果:流式细胞术结果表明，与Control组和GFP组相比，Survivin-shRNA组细胞凋亡率增加，差异有统计学意义（P＜0.05）；随着作用时间的延长，S期出现阻滞，48 h阻滞最强，显著高于对照组（P＜0.05）。MTT结果发现Survivin-shRNA可抑制HXO-RB44细胞增殖活性，与Control组和GFP组相比，差异有统计学意义（P＜0.05）；Western blot结果发现，与对照组相比，LC3表达量显著增加（P＜0.01）；而mTOR表达量降低（P＜0.01）。结论:Survivin-shRNA可促进视网膜母细胞瘤HXO-RB44细胞的凋亡和自噬水平，进而特异性杀伤肿瘤细胞。     

Survivin as a diagnostic and therapeutic marker for thyroid cancer

Thyroid cancer (TC) is known as the most prevalent form of endocrine malignancy. With regard to high heterogeneity of the nodules, problem of discriminating between benign and malignant ones in terms of pathological characteristics, as well as lack of appropriate molecular markers; significant efforts are being made to identify molecular markers that able to detect tumorous lesions. Survivin, the newest member of the family of proteins inhibiting cell apoptosis, has been recently considered as a novel molecule marker for cancer. Studies on TC have also demonstrated distinctive expression of survivin and its splice variants in cancer cells compared to normal ones. Therefore, detection of survivin expression and its new splice variants can be utilized to identify tumor nodules and distinguish them from non-cancerous ones, along with other routine laboratory methods.     

Suppression of Rotenone-Treated Human Breast Cancer Stem Cell Survival Using Survivin Inhibitor YM155 is Associated to Oxidative Stress Modulation

Background: Despite recent progress in molecular-targeted therapies, breast cancer remains the primary leading cause of cancer related death among women worldwide. Breast cancer stem cells (BCSCs) are believed to be responsible for therapy resistance and cancer recurrence. We recently demonstrated that human BCSCs (CD24-/CD44+) could survive better than their counterpart non-BCSCs (CD24-/CD44-) when treated with rotenone, possibly due to lower levels of reactive oxygen species (ROS) production, high expression of antioxidant manganese superoxide dismutase (MnSOD), and anti-apoptotic survivin. The aim of this study was to verify the role of survivin on human BCSCs survival under oxidative stress modulation by suppressing its expression using YM155, a survivin inhibitor. Methods: Human BCSCs (ALDH+ cells) were treated with YM155 for 24 h prior to treatment with rotenone for a further 6 h. We determined intracellular superoxide levels were determined using dihydroethidium assay, survivin and MnSOD expression using qRT-PCR, survivin protein level using ELISA, as well as cell viability using trypan blue exclusion and acridine orange/ethidium bromide apoptosis assay. Results: Suppression of survivin expression using YM155 could reduce the survival of rotenone-treated BCSCs, which may be associated with oxidative stress modulation, as shown by increased ROS levels and decreased MnSOD expression. We confirm that survivin is responsible for maintaining BCSCs survival under oxidative stress modulation. Furthermore, YM155 could modulate oxidative stress in BCSCs by reducing MnSOD expression and increasing ROS levels. Conclusion: YM155 treatment could be used to overcome BCSCs resistance to oxidative stress-based anticancer therapies.     

Survivin、BRAF、Notch1在甲状腺良恶性肿瘤中的差异表达及其与血清指标的关系

目的:研究Survivin、BRAF、Notch1在甲状腺良恶性肿瘤中的差异表达及其与血清指标的关系.方法:将在本院就诊的100例甲状腺癌患者和100例甲状腺腺瘤患者纳入研究,采用Real-timePCR和Western-blot检测肿瘤组织中Survivin、BRAF、Notch1的表达情况,采用酶联免疫吸附法检测血清中血管内皮生长因子(VEGF)含量.结果:甲状腺癌组织中Survivin、BRAF、Notch1的mRNA和蛋白水平均高于甲状腺腺瘤组织,且TNM分期越差,Survivin、BRAF、Notch1的表达量越高;甲状腺癌患者血清中VEGFA、VEGFB、VEGFC的含量均高于甲状腺腺瘤患者;多元线性回归显示,VEGFA、VEGFB、VEGFC均与Survivin、BRAF、Notch1呈正相关.结论:甲状腺癌组织中Survivin、BRAF、Notch1呈高表达,且与血清中血管新生指标VEGF具有良好的相关性.     

健脾益肾方对非小细胞肺癌细胞体外增殖凋亡作用的实验研究

目的:探讨健脾益肾方对非小细胞肺癌(NSCLC)细胞体外增殖凋亡的作用。方法:人NSCLC细胞系A549分为四组:空白对照组(仅加入细胞培养液)、阴性对照组(加入细胞,不进行中药处理)、实验组(加细胞加中药处理)。荧光定量PCR和Western blot分别检测Survivin、Bcl-2和Caspase-3的mRNA和蛋白表达。MTT检测细胞增殖;流式细胞术检测细胞凋亡。结果:与空白对照组相比,阴性对照组细胞在24、48、72 h的吸光度值明显升高,细胞凋亡率下降,Survivin和Bcl-2 mRNA和蛋白相对表达量上调,Caspase-3 mRNA和蛋白相对表达量下调,组间比较差异有统计学意义(P<0.05);而健脾益肾方处理的实验组24、48、72 h的吸光度值均显著降低,细胞凋亡率显著上升,Survivin和Bcl-2 mRNA和蛋白相对表达量下调,Caspase-3 mRNA和蛋白相对表达量上调,与空白对照组相比差异有统计学意义(P<0.05)。结论:健脾益肾方可通过下调Survivin和Bcl-2、上调Caspase-3表达诱导NSCLC细胞凋亡,并抑制肿瘤细胞的增殖,进而抑制NSCLC的发展。     

Survivin在舌鳞癌中的表达及其与血管内皮生长因子的相关性

目的：研究Survivin在舌鳞状细胞癌（tongue squamous cell carcinoma，TSCC）中的表达及其与血管内皮生长因子vascular endothelial growth factor，VEGF之间的相关性。方法：采用免疫组化pv9000法检测45例舌鳞癌组织Survivin、VEGF蛋白的表达。结果：Survivin、VEGF在舌鳞癌组织中表达水平为68．9％、64.4％，显著高于正常舌黏膜组（P〈0．01）。Survivin表达与舌鳞癌组织学分级、TNM分期相关（P〈0．05），与颈淋巴结转移密切相关（P〈0．01）。VEGF表达与舌鳞癌TNM分期和颈淋巴结转移密切相关（P〈0．05）。在舌鳞癌组织中Survivin、VEGF共同表达率为53.3％，其表达阳性程度呈显著正相关。结论：Survivin、VEGF的表达与舌鳞癌临床病理特征相关，Survivin、VEGF在舌鳞癌中起相互协同作用。     

口腔鳞癌中Bax,Bcl-2和Survivin蛋白表达与预后相关性研究

目的:研究凋亡相关蛋白Bax,Bcl-2及Survivin的表达与口腔鳞癌预后的相关性,确定预后判断的有效标志物。方法:采用免疫组织化学方法,检测110例口腔鳞癌患者术后石蜡切片组织中Bax、Bcl-2及Survivin蛋白的表达。通过目标蛋白阳性染色细胞比例和阳性细胞中蛋白的染色强度判定各种蛋白的表达水平;应用SAS 9.0软件中的Kaplan-Meier及Cox回归分析Bax、Bcl-2及Survivin蛋白表达与口腔鳞癌预后的相关性。结果:110例标本检测和统计分析结果表明,Bax、Bcl-2和Survivin蛋白单独表达水平与口腔鳞癌术后生存时间并无显著的相关性;Bcl-2/Bax的比值与口腔鳞癌的术后生存时间呈显著相关(P<0.05)。结论:口腔鳞癌患者组织标本中的Bcl-2/Bax值是影响预后的重要指标,提示该指标在临床上可作为口腔鳞癌患者预后判断的有效标志物。